Amplia Therapeutics Ltd

ATX

Company Profile

  • Business description

    Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

  • Contact

    350 Queen Street
    Level 17
    MelbourneVIC3000
    AUS

    T: +61 280033650

    https://www.ampliatx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2026

    Employees

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,741.9026.70-0.30%
CAC 407,790.2714.40-0.18%
DAX 4024,323.5847.100.19%
Dow JONES (US)42,319.74108.00-0.25%
FTSE 1008,810.470.57-0.01%
HKSE23,860.8046.17-0.19%
NASDAQ19,298.45162.04-0.83%
Nikkei 22537,741.61187.120.50%
NZX 50 Index12,563.4813.67-0.11%
S&P 5005,939.3031.51-0.53%
S&P/ASX 2008,515.7023.20-0.27%
SSE Composite Index3,385.691.590.05%

Market Movers